rare nrg1 fusion epidemiology forecast insight

DelveInsight’s ‘Rare NRG1 Fusion - Epidemiology Forecast to 2034’ report delivers an in-depth understanding of the disease, historical and forecasted Rare NRG1 Fusion epidemiology in the 8MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan and China.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
• China

Study Period: 2021-2034

Rare NRG1 Fusion Understanding

Rare NRG1 Fusion Overview

NRG1 (Neuregulin 1) gene fusions are potentially actionable oncogenic drivers that are present in some solid tumors. NRG1 fusions result in ErbB-mediated pathway activation and present a rational therapeutic target. Oncogenic fusions of NRG1 may cause excess accumulation of the NRG1-fusion protein at the cell surface. This causes persistent activation of ErbB receptor tyrosine kinases that drive excess activity in the mTOR and MAPK pathways and promote tumorigenesis. The NRG1 gene encodes ligands for the ERBB2 (HER2)-ERBB3 heterodimeric receptor tyrosine kinase. Gene fusions of NRG1 such as CD74-NRG1 and SLC33A2-NRG1 have been found at low frequency in a wide range of carcinomas including lung, breast, colorectal, ovarian, and pancreatic cancers and with a wide range of fusion partners.

CD74-NRG1 fusion gene has been identified in a portion of invasive mucinous adenocarcinomas (IMA) of the lung. However, the function of the CD74-NRG1 fusion gene in adenocarcinoma pathogenesis and the mechanisms by which it may impart protumorigenic characteristics to cancer stem cells (CSC) is still unclear. A range of NRG1 fusion partners beyond CD74 has been identified, and they also vary among cancer types. In NSCLC, other fusion partners include the SDC4, SLC3A2, and ATP1B1 genes. In other malignancies, the genes SETD4, TSHZ2, and ZMYM2 (ovarian cancer); ADAM9 and COX10-AS1 genes (breast cancer); and CDH1 and VTCN1 genes (pancreatic cancer) are among known fusion partners of NRG1.

Rare NRG1 Fusion Diagnosis

Fusions involving the neuregulin-1 gene (NRG1) were first identified by transcriptome sequencing of lung adenocarcinomas, which revealed fusion of CD74 to NRG1. NRG1-fusion proteins and genes in solid tumors are detected primarily using immunohistochemistry and fluorescence in situ hybridization (FISH) techniques, DNA next-generation sequencing (NGS), and targeted gene fusion panels on RNA. The gold standard for the detection of NRG1 gene fusions is RNA sequencing in comparison with DNA sequencing. Although fluorescence in situ hybridization (FISH) can be used as a pre-screening method for its detection, only genetic sequencing will allow the identification of the gene fusion. RNA-sequencing is associated with higher sensitivity for genetic rearrangements and can increase the detection of NRG1 gene fusions compared with DNA-based methods, which often do not cover the large introns in NRG1.

Epidemiology Perspective by DelveInsight

The Rare NRG1 Fusion epidemiology division provides insights about the historical and current Rare NRG1 Fusion patient pool and forecasted trends for every eight major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

In the year 2020, the total incident case of Rare NRG1 Fusion was 12,934 cases in the 8MM which are expected to grow during the study period, i.e., 2021-2034.

The disease epidemiology covered in the report provides historical as well as forecasted Rare NRG1 Fusion epidemiology [segmented as Total Incident Cases of NRG1 Fusion, Total Stage-specific Cases of NRG1 Fusion, and Total Treated cases of NRG1 Fusion] in the 8MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan and China from 2021 to 2034.

Country Wise- Rare NRG1 Fusion Epidemiology

Estimates show that the highest cases of NRG1 Fusion in the 8MM were in China, followed by the United States, Japan, Germany, France, Italy, the United Kingdom, and Spain in 2020.

• In the year 2020, the total incident case of NRG1 Fusion was 12,934 cases in the 8MM, and China, in 2020, accounted for 6,813 cases (the highest number), which will probably rise during the study period, i.e., 2021-2034.
• In the 8MM, the total stage-specific cases of NRG1 Fusion were 6,645 and 6,289 for non-metastatic and metastatic (including locally advanced), respectively in the year 2020.
• In the 8MM, the total treated cases of NRG1 Fusion were 1,604 in the year 2020.
• In the United States, the total number of incident cases of NRG1 Fusion was 2,253 cases in the year 2020 which are expected to grow during the study period, i.e., 2021-2034.
• In the year 2020, the total incident cases of NRG1 Fusion were 2,527 cases in EU-5 which are expected to grow during the study period, i.e., 2021-2034.
• In Japan, the total number of incident cases of NRG1 Fusion was 1,341 cases in the year 2020 which are expected to grow during the study period, i.e., 2021-2034.
• In China, the total number of incident cases of NRG1 Fusion was 6,813 cases in the year 2020 which are expected to grow during the study period, i.e., 2021-2034.

Scope of the Report

• The Rare NRG1 Fusion report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• The Rare NRG1 Fusion Report and Model provide an overview of the risk factors and global trends of Rare NRG1 Fusion in the eight major markets (8MM: The United States, Germany, France, Italy, Spain, and the United Kingdom, Japan, and China)
• The report provides insight about the historical and forecasted patient pool of Rare NRG1 Fusion in eight major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) Japan, and China.
• The report helps to recognize the growth opportunities in the 8MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Rare NRG1 Fusion.
• The report provides the segmentation of the Rare NRG1 Fusion epidemiology by total incident cases in the 8MM.
• The report provides the segmentation of the Rare NRG1 Fusion epidemiology by total stage-specific cases in the 8MM.
• The report provides the segmentation of the Rare NRG1 Fusion epidemiology by total treated cases in the 8MM.

Report Highlights

• 10-Year Forecast of Rare NRG1 Fusion epidemiology
• 8MM Coverage
• Total Incident Cases of Rare NRG1 Fusion
• Total Stage-specific Cases of Rare NRG1 Fusion
• Total Treated Cases of Rare NRG1 Fusion

KOL-Views

We interview KOL’s and SMEs ' opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 8MM concerning the patient population of Rare NRG1 Fusion?
• What are the key findings of the Rare NRG1 Fusion epidemiology across the 8MM and which country will have the highest number of patients during the study period (2021-2034)?
• What would be the total number of patients of Rare NRG1 Fusion across the 8MM during the study period (2021-2034)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2021-2034)?
• At what CAGR the patient population is expected to grow in the 8MM during the study period (2021-2034)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of Rare NRG1 Fusion?

Reasons to buy

The Rare NRG1 Fusion Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Rare NRG1 Fusion market
• Quantify patient populations in the global Rare NRG1 Fusion market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the gender that presents the best opportunities for Rare NRG1 Fusion therapeutics in each of the markets covered
• Understand the magnitude of the Rare NRG1 Fusion population by its severity
• The Rare NRG1 Fusion epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
• The Rare NRG1 Fusion Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population